Does Dr. EYAD ABU-HAMDA have financial conflicts of interest?

Dr. EYAD ABU-HAMDA (M.D.P.C.) has received a total of $2,103 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $2,103 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. EYAD ABU-HAMDA?

According to CMS Open Payments data, Dr. EYAD ABU-HAMDA received funding from ASTRAZENECA PHARMACEUTICALS ($372), GENZYME CORPORATION ($294), and AMGEN ($236).

Does Dr. EYAD ABU-HAMDA receive research grants or speaking fees?

Dr. EYAD ABU-HAMDA has received $2,103 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. EYAD ABU-HAMDA

M.D.P.C.Real-Time Hydrated

Specialty: Internal Medicine, Critical Care Medicine

Practice Location: FAIRFAX, VA 22031

NPI Number: 1619961638

LIFETIME INDUSTRY VALUE

$2,103

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABU-HAMDA is a verified Internal Medicine, Critical Care Medicine practitioner based in FAIRFAX, VA.

Between 2021 and 2024, Dr. ABU-HAMDA had an overall industry promotional and research financial footprint of $2,103 as recorded in the federal CMS Open Payments database.

$2,103 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABU-HAMDA's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $372 (representing 17.7% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$372

17.7%

GENZYME CORPORATION

Rank 2

$294

14%

AMGEN

Rank 3

$236

11.2%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.